Compounds > sorafenib
Page last updated: 2024-09-05

sorafenib and tak-632

sorafenib has been researched along with tak-632 in 3 studies

Compound Research Comparison

Studies
(sorafenib)		Trials
(sorafenib)		Recent Studies (post-2010)
(sorafenib)		Studies
(tak-632)		Trials
(tak-632)		Recent Studies (post-2010) (tak-632)
6,5207305,25117016

Protein Interaction Comparison

ProteinTaxonomysorafenib (IC50)tak-632 (IC50)
Serine/threonine-protein kinase Chk1Homo sapiens (human)1.4
Inhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)3.7
RAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)0.0156
Platelet-derived growth factor subunit AHomo sapiens (human)0.61
Cyclin-dependent kinase 1Homo sapiens (human)0.79
Platelet-derived growth factor receptor betaHomo sapiens (human)0.12
G2/mitotic-specific cyclin-B1Homo sapiens (human)0.79
Serine/threonine-protein kinase B-rafHomo sapiens (human)0.0201
Cyclin-A2Homo sapiens (human)0.58
Fibroblast growth factor receptor 3Homo sapiens (human)0.28
Cyclin-dependent kinase 2Homo sapiens (human)0.58
Vascular endothelial growth factor receptor 2Homo sapiens (human)0.16
Glycogen synthase kinase-3 betaHomo sapiens (human)0.5
Dual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)3.7
Angiopoietin-1 receptorHomo sapiens (human)0.74
Mitogen-activated protein kinase 14Homo sapiens (human)0.6
Aurora kinase BHomo sapiens (human)0.066

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (66.67)24.3611
2020's1 (33.33)2.80

Authors

AuthorsStudies
Blagg, BS; Garg, G; Ghosh, S; Hall, JA; Seedarala, S; Zhao, H1
Berrios, KN; Estrada, MA; Grasso, M; Marmorstein, R; Winkler, JD1
Shi, K; Wang, J; Wang, Y; Zhang, J; Zhou, E1

Reviews

1 review(s) available for sorafenib and tak-632

ArticleYear
Small-Molecule Receptor-Interacting Protein 1 (RIP1) Inhibitors as Therapeutic Agents for Multifaceted Diseases: Current Medicinal Chemistry Insights and Emerging Opportunities.
    Journal of medicinal chemistry, 2022, 11-24, Volume: 65, Issue:22

    Topics: Apoptosis; Chemistry, Pharmaceutical; Drug Discovery; Humans; Receptor-Interacting Protein Serine-Threonine Kinases

2022

Other Studies

2 other study(ies) available for sorafenib and tak-632

ArticleYear
Novobiocin Analogues That Inhibit the MAPK Pathway.
    Journal of medicinal chemistry, 2016, Feb-11, Volume: 59, Issue:3

    Topics: Antineoplastic Agents; Cell Proliferation; Cells, Cultured; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; HSP90 Heat-Shock Proteins; Humans; Mitogen-Activated Protein Kinases; Models, Molecular; Molecular Structure; Novobiocin; Signal Transduction; Structure-Activity Relationship

2016
N-(7-Cyano-6-(4-fluoro-3-(2-(3-(trifluoromethyl)phenyl)acetamido)phenoxy)benzo[d]thiazol-2-yl)cyclopropanecarboxamide (TAK632) Promotes Inhibition of BRAF through the Induction of Inhibited Dimers.
    Journal of medicinal chemistry, 2018, 06-14, Volume: 61, Issue:11

    Topics: Benzothiazoles; Cell Line, Tumor; Dimerization; Drug Design; Humans; MAP Kinase Signaling System; Models, Molecular; Nitriles; Protein Kinase Inhibitors; Protein Multimerization; Protein Structure, Quaternary; Proto-Oncogene Proteins B-raf

2018